8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 3, 2026·SEC
Material company update
Mar 11, 2026·SEC
biote Corp.(BTMD)Earnings, Financials & Key Ratios
BTMD•NASDAQ
3.1× P/E·Price updated Jun 17, 2026
Aboutbiote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.Show more
- Revenue$192M-2.5%
- EBITDA$39M+11.5%
- Net Income$27M+756.7%
- EPS (Diluted)0.74+703.5%
- Gross Margin71.46%+1.3%
- EBITDA Margin20.4%+14.4%
- Operating Margin18.5%+15.4%
- Net Margin14.07%+778.8%
BTMD Key Insights
biote Corp. (BTMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 15.7% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 10.5%
- ✓Healthy dividend yield of 2.1%
- ✓Efficient asset utilization: 1.8x turnover
✗Weaknesses
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BTMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BTMD Price & Volume
biote Corp. (BTMD) stock price & volume — 10-year historical chart
Loading chart...
BTMD Growth Metrics
biote Corp. (BTMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years10.52%
3 Years5.23%
TTM-5.63%
Profit CAGR
10 Years-
5 Years-1.5%
3 Years-
TTM-28.43%
EPS CAGR
10 Years-
5 Years-28.1%
3 Years66.61%
TTM-27.23%
Return on Capital
10 Years80.8%
5 Years27.11%
3 Years36.54%
Last Year53.27%
BTMD Recent Earnings
biote Corp. (BTMD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.06-33.3%
$0.09
Rev
$45M-2.4%
$46M
Q2 2026
Mar 11, 2026Metric
Actual
Est
EPS
$0.06+20.0%
$0.05
Rev
$46M+1.3%
$46M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.22+340.0%
$0.05
Rev
$48M+4.7%
$46M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.10+66.7%
$0.06
Rev
$49M+2.3%
$48M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.06vs $0.09-33.3% | $45Mvs $46M-2.4% |
| Q2 2026 | Mar 11, 2026 | $0.06vs $0.05+20.0% | $46Mvs $46M+1.3% |
| Q4 2025 | Nov 5, 2025 | $0.22vs $0.05+340.0% | $48Mvs $46M+4.7% |
| Q3 2025 | Aug 6, 2025 | $0.10vs $0.06+66.7% | $49Mvs $48M+2.3% |
Based on last 12 quarters of dataView full earnings history →
BTMD Peer Comparison
biote Corp. (BTMD) competitors in Physician platforms and value-based care — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HIMS | 7B | 31.89 | 62.53 | 59% | -0.56% | -2.48% | 2.34 | |
 EVAX | 20.97M | 3.32 | -2.74 | 125.12% | -102.42% | -61.46% | 0.44 | |
 AMWL | 142.02M | 8.50 | -1.43 | -1.98% | -48.16% | -33.48% | 0.02 | |
 NUVB | 1.85B | 5.33 | -8.88 | 6.99% | -102.06% | -44.1% | 0.03 | |
 GDRX | 904.7M | 2.61 | 30.60 | 0.57% | 3.74% | 4.75% | 0.10 | |
 DOCS | 3.82B | 20.45 | 20.87 | 13.05% | 30.4% | 19.36% | 0.01 | |
 ABBV | 391.3B | 221.23 | 93.35 | 8.57% | 6.91% | 62.15% | ||
 AVDL | 2.1B | 21.64 | -42.43 | 5.05% | -0.11% | -0.33% | 0.02 |
Compare BTMD vs Peers
biote Corp. (BTMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BTMD Income Statement
biote Corp. (BTMD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 109.98M | 116.57M | 139.4M | 164.96M | 185.36M | 197.19M | 192.22M | 188.16M |
Revenue Growth % | - | 5.99% | 19.58% | 18.34% | 12.37% | 6.38% | -2.52% | -5.63% |
Cost of Goods Sold | 43.56M | 44.93M | 48.82M | 54.58M | 57.88M | 58.13M | 54.86M | 56.23M |
COGS % of Revenue | 39.61% | 38.54% | 35.02% | 33.08% | 31.22% | 29.48% | 28.54% | - |
Gross Profit | 66.41M▲ 0% | 71.64M▲ 7.9% | 90.58M▲ 26.4% | 110.38M▲ 21.9% | 127.48M▲ 15.5% | 139.06M▲ 9.1% | 137.36M▼ 1.2% | 131.93M▲ 0% |
Gross Margin % | 60.39% | 61.46% | 64.98% | 66.92% | 68.78% | 70.52% | 71.46% | 70.12% |
Gross Profit Growth % | - | 7.87% | 26.44% | 21.86% | 15.49% | 9.08% | -1.22% | - |
Operating Expenses | 42.88M | 39.86M | 56.02M | 171.1M | 98.83M | 107.45M | 101.81M | 102.91M |
OpEx % of Revenue | 38.99% | 34.19% | 40.19% | 103.73% | 53.32% | 54.49% | 52.97% | - |
Selling, General & Admin | 39.29M | 37.43M | 53.96M | 171.1M | 0 | 107.45M | 101.81M | 102.91M |
SG&A % of Revenue | 35.73% | 32.11% | 38.71% | 103.73% | - | 54.49% | 52.97% | - |
Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
R&D % of Revenue | - | - | - | - | - | - | - | - |
Other Operating Expenses | 3.59M | 2.43M | 2.06M | 0 | 98.83M | 0 | 0 | 0 |
Operating Income | 23.53M▲ 0% | 31.78M▲ 35.1% | 34.56M▲ 8.7% | -60.72M▼ 275.7% | 28.66M▲ 147.2% | 31.61M▲ 10.3% | 35.55M▲ 12.5% | 29.03M▲ 0% |
Operating Margin % | 21.39% | 27.26% | 24.79% | -36.81% | 15.46% | 16.03% | 18.5% | 15.43% |
Operating Income Growth % | - | 35.08% | 8.75% | -275.7% | 147.19% | 10.31% | 12.46% | - |
EBITDA | 24.36M | 32.92M | 35.96M | -58.52M | 29.45M | 35.19M | 39.22M | 31.84M |
EBITDA Margin % | 22.15% | 28.24% | 25.8% | -35.48% | 15.89% | 17.84% | 20.4% | 16.92% |
EBITDA Growth % | - | 35.14% | 9.24% | -262.74% | 150.32% | 19.47% | 11.47% | -6.78% |
D&A (Non-Cash Add-back) | 832K | 1.14M | 1.4M | 2.2M | 794K | 3.57M | 3.67M | 2.81M |
EBIT | 23.46M | 31.78M | 34.58M | 5.76M | 38.74M | 12.02M | 35.55M | 18.36M |
Net Interest Income | -2.08M | -2.42M | -1.67M | -4.05M | -6.36M | -11M | -10.96M | -6.08M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 2.08M | 2.42M | 1.67M | 4.05M | 6.36M | 11M | 10.96M | 6.08M |
Other Income/Expense | -2.15M | -2.43M | -1.66M | 62.43M | -28.78M | -30.59M | 2.03M | -5.56M |
Pretax Income | 21.38M▲ 0% | 29.35M▲ 37.3% | 32.91M▲ 12.1% | 1.71M▼ 94.8% | -123K▼ 107.2% | 1.02M▲ 926.0% | 37.58M▲ 3599.2% | 23.47M▲ 0% |
Pretax Margin % | 19.44% | 25.18% | 23.61% | 1.04% | -0.07% | 0.52% | 19.55% | 12.47% |
Income Tax | 93K | 189K | 286K | 388K | 2.68M | 970K | 5.99M | 5.03M |
Effective Tax Rate % | 0.43% | 0.64% | 0.87% | 22.66% | -2180.49% | 95.47% | 15.93% | 21.45% |
Net Income | 21.29M▲ 0% | 29.16M▲ 37.0% | 32.62M▲ 11.9% | -969K▼ 103.0% | 3.32M▲ 442.2% | 3.16M▼ 4.8% | 27.05M▲ 756.7% | 15.6M▲ 0% |
Net Margin % | 19.36% | 25.02% | 23.4% | -0.59% | 1.79% | 1.6% | 14.07% | 8.29% |
Net Income Growth % | - | 36.99% | 11.85% | -102.97% | 442.21% | -4.79% | 756.67% | -28.43% |
Net Income (Continuing) | 21.29M | 29.16M | 32.62M | 1.32M | -2.81M | 46K | 31.6M | 18.04M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | -13.81M | -7.15M | 3.73M | 8.14M | 8.14M |
EPS (Diluted) | 2.81▲ 0% | 3.85▲ 37.0% | -0.87▼ 122.6% | 0.16▲ 118.4% | 0.13▼ 18.8% | 0.09▼ 29.2% | 0.74▲ 703.5% | 0.43▲ 0% |
EPS Growth % | - | 37.01% | -122.6% | 118.39% | -18.75% | -29.15% | 703.47% | -27.23% |
EPS (Basic) | 2.81 | 3.85 | -0.87 | 0.16 | 0.13 | 0.09 | 0.86 | - |
Diluted Shares Outstanding | 7.57M | 7.57M | 7.57M | 8.06M | 25.71M | 34.27M | 36.67M | 36M |
Basic Shares Outstanding | 7.57M | 7.57M | 7.57M | 8.06M | 25.71M | 34.27M | 31.28M | 30.65M |
Dividend Payout Ratio | 266.05% | 45.67% | 34.96% | - | 262.18% | 150.27% | 6.39% | - |
BTMD Balance Sheet
biote Corp. (BTMD) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 19.3M | 27.82M | 47.09M | 101.18M | 122.34M | 68.13M | 54.67M | 36.36M |
Cash & Short-Term Investments | 10.49M | 17.21M | 26.77M | 79.23M | 89M | 39.34M | 24.12M | 5.32M |
Cash Only | 10.49M | 17.21M | 26.77M | 79.23M | 89M | 39.34M | 24.12M | 5.32M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 4.02M | 4.72M | 5.23M | 6.95M | 8.17M | 7.7M | 6.87M | 7.4M |
Days Sales Outstanding | 13.33 | 14.78 | 13.7 | 15.37 | 16.1 | 14.26 | 13.04 | 15.23 |
Inventory | 3.92M | 4.32M | 9.62M | 11.18M | 17.31M | 14.85M | 19.06M | 19.88M |
Days Inventory Outstanding | 32.82 | 35.13 | 71.89 | 74.79 | 109.15 | 93.21 | 126.84 | 109.58 |
Other Current Assets | 0 | 0 | 3.94M | 0 | 308K | 111K | 4.62M | 3.76M |
Total Non-Current Assets | 4.59M | 4.76M | 7.25M | 10.47M | 32.95M | 54.24M | 52.94M | 52.68M |
Property, Plant & Equipment | 2.76M | 2.17M | 2.69M | 3.56M | 3.1M | 10.22M | 13.45M | 13.26M |
Fixed Asset Turnover | 39.79x | 53.84x | 51.80x | 46.39x | 59.89x | 19.30x | 14.29x | 14.33x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 5.83M | 5.83M | 5.83M |
Intangible Assets | 1.82M | 2.6M | 4.55M | 5.07M | 4.97M | 9.38M | 4.27M | 9.03M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | -4.59M | 0 | 0 | 0 | 0 | 72K | 4.6M | 72K |
Total Assets | 23.89M▲ 0% | 32.59M▲ 36.4% | 54.33M▲ 66.7% | 111.64M▲ 105.5% | 155.29M▲ 39.1% | 122.37M▼ 21.2% | 107.61M▼ 12.1% | 89.03M▲ 0% |
Asset Turnover | 4.60x | 3.58x | 2.57x | 1.48x | 1.19x | 1.61x | 1.79x | 1.82x |
Asset Growth % | - | 36.4% | 66.72% | 105.49% | 39.1% | -21.2% | -12.06% | -17.14% |
Total Current Liabilities | 13.51M | 11.71M | 17.31M | 18.77M | 22.21M | 51.51M | 44.99M | 28.23M |
Accounts Payable | 3.19M | 2.44M | 4.35M | 4.11M | 4.16M | 5.81M | 6.83M | 8.24M |
Days Payables Outstanding | 26.72 | 19.86 | 32.52 | 27.5 | 26.2 | 36.5 | 45.42 | 37.79 |
Short-Term Debt | 5M | 5M | 5M | 6.25M | 6.25M | 6.25M | 6.84M | 6.86M |
Deferred Revenue (Current) | 0 | 2.04M | 1.71M | 1.97M | 3M | 2.96M | 3.02M | 12.08M |
Other Current Liabilities | 2.58M | 1.36M | 2.21M | 4.22M | 6.07M | 30.32M | 28.31M | 10.28M |
Current Ratio | 1.43x | 2.38x | 2.72x | 5.39x | 5.51x | 1.32x | 1.22x | 1.29x |
Quick Ratio | 1.14x | 2.01x | 2.16x | 4.80x | 4.73x | 1.03x | 0.79x | 0.58x |
Cash Conversion Cycle | 19.43 | 30.04 | 53.07 | 62.66 | 99.04 | 70.97 | 94.47 | 87.02 |
Total Non-Current Liabilities | 43.31M | 37.95M | 32.89M | 151.15M | 169.63M | 173.06M | 113.02M | 108.76M |
Long-Term Debt | 41.52M | 36.74M | 31.96M | 112.09M | 106.63M | 101.2M | 100.78M | 99.42M |
Capital Lease Obligations | 614K | 375K | 127K | 1.93M | 1.68M | 2.89M | 2.3M | 9.49M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1.17M | 0 | 0 | 36.21M | 59.99M | 67.41M | 8.84M | 6.28M |
Total Liabilities | 56.82M | 49.66M | 50.2M | 169.92M | 191.84M | 224.57M | 158.01M | 136.99M |
Total Debt | 47.13M | 42.35M | 37.34M | 120.43M | 114.87M | 110.86M | 109.92M | 108.42M |
Net Debt | 36.65M | 25.15M | 10.57M | 41.2M | 25.87M | 71.52M | 85.8M | 103.1M |
Debt / Equity | - | - | 9.05x | - | - | - | - | -2.26x |
Debt / EBITDA | 1.93x | 1.29x | 1.04x | - | 3.90x | 3.15x | 2.80x | 3.41x |
Net Debt / EBITDA | 1.50x | 0.76x | 0.29x | - | 0.88x | 2.03x | 2.19x | 3.24x |
Interest Coverage | 11.27x | 13.10x | 20.67x | 1.42x | 6.09x | 1.09x | 3.24x | 3.02x |
Total Equity | -32.93M▲ 0% | -17.07M▲ 48.1% | 4.13M▲ 124.2% | -58.27M▼ 1512.7% | -36.55M▲ 37.3% | -102.2M▼ 179.6% | -50.4M▲ 50.7% | -47.95M▲ 0% |
Equity Growth % | - | 48.14% | 124.16% | -1512.7% | 37.29% | -179.65% | 50.69% | 186.88% |
Book Value per Share | -4.35 | -2.25 | 0.54 | -7.23 | -1.42 | -2.98 | -1.37 | -1.33 |
Total Shareholders' Equity | -32.93M | -17.07M | 4.13M | -44.46M | -29.4M | -105.93M | -58.54M | -56.09M |
Common Stock | 0 | 0 | 0 | 6K | 6K | 4K | 4K | 4K |
Retained Earnings | -32.9M | -17.05M | 4.17M | -44.46M | -29.39M | -100.3M | -49.55M | -46.03M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | -5.6M | -8.96M | -10.04M |
Accumulated OCI | -33K | -23K | -40K | -5K | -12K | -35K | -29K | -27K |
Minority Interest | 0 | 0 | 0 | -13.81M | -7.15M | 3.73M | 8.14M | 8.14M |
BTMD Cash Flow Statement
biote Corp. (BTMD) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | 25.35M | 26.43M | 33.72M | -9.16M | 26.88M | 45.24M | 35.19M | 32.63M |
Operating CF Margin % | 23.05% | 22.67% | 24.19% | -5.55% | 14.5% | 22.94% | 18.31% | - |
Operating CF Growth % | - | 4.22% | 27.61% | -127.16% | 393.58% | 68.3% | -22.21% | -116.77% |
Net Income | 21.29M | 29.16M | 32.62M | 1.32M | 3.32M | 46K | 27.05M | 15.6M |
Depreciation & Amortization | 832K | 1.14M | 1.4M | 2.2M | 2.99M | 3.57M | 3.67M | 3.79M |
Stock-Based Compensation | 0 | 0 | 0 | 82.18M | 9.06M | 8.73M | 8.92M | 6.79M |
Deferred Taxes | 0 | 0 | 0 | -743K | 721K | -2.9M | 3.98M | 3.26M |
Other Non-Cash Items | 837K | 1.71M | 1.16M | -58.3M | 19.72M | 25.85M | -165K | 2.15M |
Working Capital Changes | 2.4M | -5.59M | -1.46M | -35.81M | -8.93M | 9.93M | -8.25M | -1.41M |
Change in Receivables | -714K | -1.48M | -752K | -1.56M | -505K | -2.27M | -958K | -147K |
Change in Inventory | 1.3M | -904K | -5.76M | -1.71M | -6.1M | 3.71M | -6.24M | -6.89M |
Change in Payables | 1.22M | -884K | 1.6M | 416K | -165K | 1.54M | 1.01M | 4.9M |
Cash from Investing | -1.67M | -1.39M | -3.81M | -1.84M | -2.71M | -18.8M | -6.86M | -6.18M |
Capital Expenditures | -704K | -295K | -1.45M | -333K | -359K | -6.43M | -5.01M | -4.55M |
CapEx % of Revenue | 0.64% | 0.25% | 1.04% | 0.2% | 0.19% | 3.26% | 2.61% | 2.42% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | -11.84M | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | -968K | -1.1M | -2.36M | -1.5M | -2.35M | -526K | -1.85M | -1.63M |
Cash from Financing | -13.55M | -18.32M | -20.34M | 63.46M | -14.38M | -76.08M | -43.55M | -62.84M |
Debt Issued (Net) | 44.19M | -5M | -5M | 84.38M | -6.25M | -6.25M | -1.25M | -1.25M |
Equity Issued (Net) | 0 | 0 | 0 | 18K | 144K | -5.32M | -3M | -4.07M |
Dividends Paid | -56.63M | -13.32M | -11.4M | -12.89M | -8.69M | -4.74M | -1.73M | -1.44M |
Share Repurchases | 0 | 0 | 0 | -424K | 0 | -5.6M | -3.37M | -4.44M |
Other Financing | -1.11M | 0 | -3.94M | -8.05M | 420K | -59.77M | -37.58M | -56.08M |
Net Change in Cash | 10.12M▲ 0% | 6.72M▼ 33.6% | 9.56M▲ 42.2% | 52.47M▲ 448.9% | 9.77M▼ 81.4% | -49.66M▼ 608.2% | -15.22M▲ 69.4% | -36.38M▲ 0% |
Free Cash Flow | 23.68M▲ 0% | 25.03M▲ 5.7% | 29.91M▲ 19.5% | -10.99M▼ 136.8% | 24.17M▲ 319.8% | 38.81M▲ 60.6% | 30.18M▼ 22.2% | 28.69M▲ 0% |
FCF Margin % | 21.53% | 21.47% | 21.46% | -6.67% | 13.04% | 19.68% | 15.7% | 15.25% |
FCF Growth % | - | 5.7% | 19.5% | -136.76% | 319.83% | 60.58% | -22.25% | -22.05% |
FCF per Share | 3.13 | 3.30 | 3.95 | -1.36 | 0.94 | 1.13 | 0.82 | 0.80 |
FCF Conversion (FCF/Net Income) | 1.19x | 0.91x | 1.03x | 9.45x | 8.11x | 14.33x | 1.30x | 1.84x |
Interest Paid | 1.63M | 2.49M | 1.46M | 4.43M | 9.48M | 9.54M | 0 | 4.03M |
Taxes Paid | 178K | 189K | 171K | 282K | 4.43M | 2.59M | 0 | 2.23M |
BTMD Key Ratios
biote Corp. (BTMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | 790.76% | - | - | - | - | -25.72% |
Return on Invested Capital (ROIC) | 404.3% | 227.68% | - | - | - | 1129.32% | 77.14% |
Gross Margin | 61.46% | 64.98% | 66.92% | 68.78% | 70.52% | 71.46% | 70.12% |
Net Margin | 25.02% | 23.4% | -0.59% | 1.79% | 1.6% | 14.07% | 8.29% |
Debt / Equity | - | 9.05x | - | - | - | - | -2.26x |
Interest Coverage | 13.10x | 20.67x | 1.42x | 6.09x | 1.09x | 3.24x | 3.02x |
FCF Conversion | 0.91x | 1.03x | 9.45x | 8.11x | 14.33x | 1.30x | 1.84x |
Revenue Growth | 5.99% | 19.58% | 18.34% | 12.37% | 6.38% | -2.52% | -5.63% |
Related:BTMD Dividend History·BTMD Revenue History·BTMD Price History·BTMD P/E History·BTMD Financial Ratios·BTMD Institutional Holders
BTMD SEC Filings & Documents
biote Corp. (BTMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
BTMD Frequently Asked Questions
biote Corp. (BTMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
biote Corp. (BTMD) reported $188.2M in revenue for fiscal year 2025. This represents a 71% increase from $110.0M in 2019.
biote Corp. (BTMD) saw revenue decline by 2.5% over the past year.
Yes, biote Corp. (BTMD) is profitable, generating $15.6M in net income for fiscal year 2025 (14.1% net margin).
Dividend & Returns
Yes, biote Corp. (BTMD) pays a dividend with a yield of 2.07%. This makes it attractive for income-focused investors.
biote Corp. (BTMD) generated $28.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.